treatment for vaginal infections. Partners in the program are Link Medical Research in Norway and Nottingham University Hospitals in the UK.Vaginal infections are a common problem, and current treatments such as antibiotics are not always effective. According to FTI, the justification to select Gedea Biotech as a recipient of the funding is based on, not only the significant medical need, but also on the resultant opportunity to replace current treatments involving antibiotics. Several strains of bacteria and fungi are already resistant to current treatments.
Annette Säfholm, CEO at Gedea Biotech, comments: “We believe that our new treatment, which has already shown promising results in a recently finalized clinical study in patients with bacterial vaginosis, will benefit both patients and healthcare. We are therefore delighted to have received this funding enabling us to launch the product earlier than otherwise would have been the case. We now look forward to initiating the work on our next clinical trial in Europe, together with our partners in Norway and the UK. We expect to launch our first product, that treats and prevents bacterial vaginosis in 2021.”
Collaboration partners for the work are the CRO company Link Medical from Norway with whom Gedea Biotech has a long-standing relationship and the University of Nottingham Hospitals, home to the lead clinic for the work.
For further information Annette Säfholm, CEO Gedea Biotech
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 878775